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Abstract: The many interesting physical and chemical properties of carbon nanotubes (CNT) make it one of the most commer-
cially attractive materials in the era of nanotechnology. Here, we review the recent publications on in vivo biodistribution of pris-
tine and functionalized forms of single-walled and multi-walled CNT. Pristine CNT remain in the lung for months or even years
after pulmonary deposition. If cleared, the majority of CNT move to the gastrointestinal (GI) tract via the mucociliary escalator.
However, there appears to be no uptake of CNT from the GI tract, with a possible exception of the smallest functionalized
SWCNT. Importantly, a significant fraction of CNT translocate from the alveolar space to the near pulmonary region including
lymph nodes, subpleura and pleura (<7% of the pulmonary deposited dose) and to distal organs including liver, spleen and bone
marrow (~1%). These results clearly demonstrate the main sites of long-term CNT accumulation, which also includes pleura, a
major site for fibre-induced pulmonary diseases. Studies on intravenous injection show that CNT in blood circulation are cleared
relatively fast with a half-life of minutes or hours. The major target organs were the same as identified after pulmonary exposure
with the exception of urine excretion of especially functionalized SWCNT and accumulation in lung tissue. Overall, there is evi-
dence that CNT will primarily be distributed to the liver where they appear to be present at least one year after exposure.
Amongst the many interesting materials refined in the era of
nanotechnology, carbon nanotubes (CNT) are one of the most
celebrated and technically attractive manufactured nanomateri-
als to date. They are frequently praised as the new wonder
material of nanotechnology. These nanometre-thin hollow
tubes, with their lightness, conductivity and extreme strength
and stability, have shown many promising properties within
material science, coatings, electronics, as well as biomedicine;
and they are already used in a number of materials and prod-
ucts [1]. It appears without question that material scientists
will generate new possibilities with CNT as well as will
improve a variety of industrial, consumer and medical prod-
ucts. Everything from reinforcement of skyscrapers to clothes,
from electronics to drug delivery, is envisioned.
Several companies have engaged in commercial scale pro-
duction or utilization of CNT, and they are available world-
wide. The global market for CNT products was estimated to
reach a trade value of 2.26 billion in 2015 and to reach USD
5.64 billion by 2020 [2]. The rapid increase is explained by
both the extraordinary properties by CNT and the increasing
ability to mass-produce at commercially attractive prices.
A rapid increase in production and products inevitably leads
to increased occupational, consumer and environmental
exposure. As for many other nanomaterials [3,4], this has
raised concerns for CNT, especially because they have physi-
cal traits similar to asbestos [5]. Asbestos was previously
praised as a wonder material, but exposure has since been
shown to increase the risk of developing mesothelioma, lung
cancer, asbestosis, pleural plaque and effusion [6]. The most
important similar characteristics between CNT and asbestos
are the very poor solubility and their fibrous morphology with
some CNT materials having a long, rigid needle-like appear-
ance (high aspect (length over diameter) ratio). Consequently,
CNT longer than 5 lm are thus in compliance with the WHO
fibre paradigm. Such fibres are thin enough to be inhaled and
reach the alveolar region, long enough to evade phagocytic
engulfment and highly biopersistent [5]. These characteristics
make pulmonary toxicity and further translocation to, for
example, the pleura possible for an extended period of time.
Such concerns are a natural impediment to widespread tech-
nological use of CNT and toxicological results have so far not
eased the concern that at least some CNT may be able to
induce serious human health effects [7–9]; especially, the two
OECD guideline studies by Ma-Hock et al. and Pauluhn
[10,11] have been noticed with results clearly showing pro-
longed pulmonary inflammation and granulomas. Less effect
was observed at lowest tested dose (0.1 mg/m3), and this was
suggested as the no observable effect level (NOEL). For the
latter study, 0.05 mg/m3 was suggested as occupational
exposure limit (OEL) [12].
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The most studied CNT (MWCNT-7/XNRI-7) has been cate-
gorized as possible carcinogenic to human beings by Interna-
tional Agency for the Research on Cancer (IARC) as group
2B. All other CNT are not yet classifiable due to limited toxi-
cological research [9]. However, recent publications show that
the profile of the overall global transcription and the acute
phase response was very similar after pulmonary exposure in
mice to two multi-walled carbon nanotubes (MWCNT) with
quite different dimensions (short L:0.9 lm, D:11 nm; long
4.1 lm, 67 nm) [13,14]. Additionally, a high degree of con-
cordance was also observed when comparing global transcrip-
tion profiles to those of MWCNT-7 [14,15], indicating that
more research may lead to further CNT being classified by
IARC. Using a battery of 10 commercial MWCNT, the same
group also identified BET surface area as a predictor for pul-
monary inflammation, but inversely correlating with genotoxi-
city in BAL cells and lung tissue. This indicates that thicker
MWCNT may cause less inflammation, but more genotoxicity
[16].
Despite these toxicological considerations, carefully tailored
CNT are still highly interesting for nanomedicine (drug deliv-
ery, targeting, visualization, etc.) as they possess some unique
characteristics leading to possibilities that may outweigh the
challenges and toxicity. Some can absorb a wide spectrum of
light and emit near-infrared (NIR) light traceable with low
interference in biological tissues. If irradiated with NIR light,
CNT produce heat that could be used for killing nearby cells.
They are stable even in harsh environments, which means safe
passage to targeted cells for materials loaded in the core. If
the CNT are surface-modified to hydrophilicity, this could
include a load of highly hydrophobic chemicals [17].
Content and Aims
In the present MiniReview, we discuss up-to-date knowledge
of in vivo biodistribution of CNT. As translocation is the most
likely hypothesis to explain toxicity at sites distal from entry,
it is critical information for a hazard evaluation. By identifying
tissues where CNT accumulate, tissues with potential target
effects are also identified. Therefore, the biodistribution is
described and evaluated after all exposure routes: inhalation or
other pulmonary deposition methods; oral gavage and uptake
through the GI tract; distribution after IV and peritoneal depo-
sition. Both single-walled (SWCNT) and multi-walled carbon
nanotubes (MWCNT) (pristine and functionalized) are
included in this MiniReview. Finally, as many different CNT
detection methods have been used, greatly varying in sensitiv-
ity and reliability, results are discussed based on the views of
the authors of the present paper on the reliability of the
methods.
Search Strategy and Selection of Studies for the Review
Publications were identified by PubMed and Google Scholar
searches by use of combinations of keywords for the material
(i.e. carbon nanotube, multi-walled carbon nanotube, single-
walled carbon nanotube, CNT, SWCNT, MWCNT, SWNT,
MWNT), methods (i.e. biodistribution, distribution, pharma-
cokinetics, kinetics) and species (i.e. in vivo, animal, mice,
mouse, rat rats, rabbit and rabbits). The abstracts were
screened for information regarding experimental results on
biodistribution of CNT. Overall searches using combinations
of several keywords tended to under-report many studies (e.g.
approximately 235 publications were identified in PubMed
using the terms above). Thus, more simple searches were also
used as well as specific searches on authors of identified pub-
lications. The publications were included after a critical assess-
ment of the methodology (see later section on measurement of
CNT in tissues) and transparency of the published results.
Publications on experiments where CNT were modified for
specific targeting (e.g. tumour targeting) were not included.
Publications where translocation was identified, but not
attempted quantified, have not been included in the review
either. This MiniReview encompasses only publications on
animal studies.
Structure of Carbon Nanotubes
Carbon nanotubes comprise a highly variable group of hollow
fibrous materials, which generally are depicted with either a
single-walled (SW), double-walled (DW) or a multi-walled
(MW) graphene-like tube (fig. 1). As implied by the name,
SWCNT consists of a monolayer of a seamless rolled sheet of
graphene. DWCNT and MWCNT consist of two and more of
such rolled and stacked sheets of graphene. The diameters and
lengths are typically in the range of 0.7–2.5 nm and 0.5–
50 lm, 1.3–5 nm and 0.5–40 lm, 4–150 nm and 0.5–
150 lm, for SW, DW and MWCNT, respectively [1]. Further
variability and complexity is added by the presence of various
impurities, levels of purification, rolling angle and chemical
functionalizations. The apparent large variability in CNT types
and purities makes it uncertain whether CNT, from a regula-
tory point of view, can be considered as one material at all or
they should be grouped according to selected physical and
chemical characteristics.
How do CNT Enter the Human Body?
For hazardous particulates or fibres to affect human health,
they must be internalized by inhalation, ingestion or injection.
The highest unintentional CNT exposure will occur in occupa-
tional settings where CNT are produced, harvested, purified,
functionalized, mixed and bagged. Although CNT exposure is
negligible in the closed-reactor synthesis procedures, a parti-
cle/dust concentration (CNT and other) of 286 lg/m3 has been
measured during harvesting [18]. Up to 332 lg/m3 (CNT and
carbon black) have been observed during handling of CNT
after opening a blender mixing composites in an unventilated
area [19]. In occupational settings, the most important expo-
sure route will be via inhalation and to a much lesser extent
dermal contact. Ingestion will occur as a secondary conse-
quence of swallowing fibres cleared from the pulmonary sys-
tem via the mucociliary escalator. Additionally, an exposure
could occur via hand-to-mouth contact.
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Carbon nanotubes are envisioned in nanomedical applica-
tions such as imaging, drug delivery and gene therapy. Such
deliberate exposure would likely take place via ingestion, sub-
cutaneous or IV/IP injection. However, as much remains
unknown about the transport mechanisms, fate and especially
adverse health effects of CNT, a biomedical/nanomedicine
application of CNT is not believed to reach the market in the
near future. Also, as discussed in [17], we still have not seen
‘any real-life biotechnological CNT breakthrough justify tak-
ing these materials forward into the clinic’.
How is CNT Measured in Tissue?
Direct detection.
Carbon nanotubes are difficult to detect visually in tissues
unless they occur in large agglomerates. It is time-consuming
to identify CNT and especially to give a semi-quantitative esti-
mate of the deposited dose. However, a direct identification or
visualization is highly important as it eliminates many of the
uncertainties coupled to indirectly measured CNT by chemical
or physical analysis of tracers.
Microscopy. Light and especially electron microscopy are
popular methods to demonstrate the presence of CNT in
tissues. It is often used to support other detection techniques.
Detection of CNT may be a major challenge in secondary
exposed organs where minimal mass concentrations are
expected. However, when detected, the special structure of
CNT is often easily identified, although certain cellular
structures (crystalline bodies caused by eosinophilic crystalline
pneumonia) closely resemble CNT [20]. A recently developed
technique is hyperspectral microscopy, which identifies
nanomaterials based on their signature refractive index [21].
This enables an easier identification of CNT in tissues. As
with all microscopic techniques, it is limited to a qualitative
detection of CNT. In order to make it semiquantitative,
Mercer et al. performed an approach by extrapolating the
amount of CNT detected in five scored slides to whole
organs. Although such scores come with large uncertainties,
they are important as they represent a direct identification of
CNT in tissues.
Raman. Raman spectroscopy can identify CNT via the
characteristic inelastic scattering of laser light. It is able to
detect both agglomerated and individual CNT [22]; especially,
it has been used in a range of studies for the detection of
SWCNT [23–27]. However, even though the specificity is
high, the sensitivity is not always sufficient. One reported a
detection limit of 0.04 lg/ml blood (0.2% of the dose/g) and
0.2 lg/ml (1% of the dose/g) in homogenized and solubilized
tissues [24]. Others report higher detection limits.
Additionally, changes to the CNT structure may weaken the
signal intensity and render the material impossible to detect in
tissue slides. Such structural damage of CNT will likely occur
during longer in vivo studies and will lead to detection being
less quantitative.
Near-infrared fluorescence. The use of near-infrared (NIR)
fluorescence is in general a promising way of detecting
SWCNT or other markers in vivo. The most useful of detected
wavelengths (emitted after laser excitation) for SWCNT are
700–900 nm or around 1100–1400 nm. These are often
termed ‘the biological transparency windows’ due to low
optical scattering, low autofluorescence and low absorption
from haemoglobin and water in tissues. This has been used
both in tissue sections and in microscopic preparation to
detect bulk SWCNT or individual SWCNT [28]. Signal
intensity does decay with tissue depth, but it has been shown
that SWCNT can be detected several millimetres inside tissue
[29].
Indirect detection.
For the detection sensitivity of CNT in tissues, radiolabelling
methods are better than Raman spectroscopy, NIR fluores-
cence and microscopy. However, as sensitivity increases, the
Fig. 1. Illustration of graphene (A) rolled up and welded into a seamless cylindrical single (B), double (C) or multi-walled (D) carbon nanotube.
Possibilities are endless for surface modifications. Illustrated are carboxylation and amine functionalization (E). SWCNT, single-walled carbon nan-
otubes; DWCNT, double-walled carbon nanotubes; MWCNT, multi-walled carbon nanotubes. Reprinted with permission from Chemistry Central
[8].
© 2016 The Authors. Basic & Clinical Pharmacology & Toxicology published by John Wiley & Sons Ltd on behalf of Nordic Association for the Publication of BCPT
(former Nordic Pharmacological Society)
32 NICKLAS RAUN JACOBSEN ET AL. MiniReview
reliability often decreases. The stability of the labelling should
be determined over time in a harsh and realistic biological
environment (fig. 2).
Radioactivity and metal tracers. Many different radiotracers
exist and are used as a proxy for the detection of CNT. The
best are the skeleton 13C-enriched SWCNT used by Yang
et al. [30] and especially radioactive 14C MWCNT used by
Czarny et al. [31]. Both have the 13C or 14C as part of the
atomic CNT structure and the activity can thus not detach
from the CNT. Biodistribution was detected via isotope ratio
(13C/12C) mass spectroscopy. However, the relatively high
presence of 13C in biological tissues (~1.1% of C) affects the
sensitivity of the technique. The detection limit was reported
to be 1 lg/g tissue by Yang, which makes the detection of
smaller deposited doses difficult. This was alleviated by use of
14C. Czarny et al. [31] demonstrated a very strong radioactive
signal, which was accomplished by a ratio of 1/17 (14C/12C)
in the MWCNT. The detection limit was reported to be
0.2 pg, equivalent to 22 intact CNT in tissue samples [31].
Another study used MWCNT with 14C bonded covalently
directly to the surface of the tube. As the C-C bond is extre-
mely strong and situated in as close proximity to the tube as
possible, this radioactive label appears highly robust. The
detection limit of 10 pg was also relative low [32]. Others
have used radiolabeling located at similar distance from the
CNT, using weaker covalent bonds (dissociation energy)
(125I-taurine-, 125I-Tween-MWCNT) [33,34]. The size and nat-
ure of iodine makes the C-I bond much more labile than the
C-C bond, which increases the risk for radioactive iodine ions
being detached from the CNT lattice structure. Another
approach has been to load isotopes (125I) or metal tracers (Ni,
Gd, Pt) inside or on the tube [35–37]. Again, the chemical
bond to the tube is important. In one paper, a detection limit
of 0.01 lg/ml (mineralized acid-treated tissue) of Ni was men-
tioned. However, as 0.53% Ni (w/w) was in the CNT, it does
not allow for the detection of smaller fractions of translocated
material.
It is of great concern that as distance between CNT and tra-
cer increases so does the possibility of detachment of tracer.
This may lead to a biased quantification of CNT in tissue
samples because of detection of free radiotracers. Examples of
larger constructs and long distance between tracer and tube
are 14C-taurine [38], 99mTc linked to MWCNT via glu-
cosamine [39]. A large number of publications have used
radiotracers, which have been anchored to larger molecules
such as diethylene-triamine-penta-acetic-acid dianhydride
(DTPA) or 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic
acid (DOTA) by a co-ordination (complex) bond. These com-
plexes are attached to the CNT surface (fig. 2). As radiotrac-
ers, 111In [40–47], 64Cu [48] and 86Y [46,49] have been used
in these constructs. It is very likely that such constructs are
stable ex situ, but stability may be strongly reduced by the
complex in vivo milieu. Table 1 summarizes the strengths and
weaknesses of the discussed methods for detecting CNT in tis-
sues. It should be noted that all methods (except structurally
build-in detection of CNT and to a certain extent microscopy)
suffer from the possibility that the structure of CNT may
change over time releasing tracers or decreasing measured
signal.
Biodistribution
With the great potential of CNT products, it is vital to deter-
mine the biodistribution, persistence and clearance of CNT as
part of a hazard characterization. Below is a presentation of
Fig. 2. Examples of the various indirect detections of SWCNT/MWCNT. The illustration is based on drawings and/or descriptions in the below-
mentioned biodistribution papers. AF488 and AF680 are Alexa flour fluorophores. DOTA, 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid;
DTPA, diethylen-triamine-penta-acetic dianhydride. There are different examples of how DOTA and DTPA are attached to the CNT and of which
tracers are used. *Our proposed structure (of several possibilities) for 99mTc-glucosamine-MWCNT used by [39].
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the original literature on biodistribution of CNT from primary
deposition in airways, gastrointestinal tract, the bloodstream
and the peritoneum. All discussed papers are summarized in
table S1.
Inhalation and instillation (and biological persistence).
Inhalation is the major exposure route for particles. It has
been shown that inhaled CNT have a very long pulmonary
half-life (months to years) and thus persist in the alveoli and
lung tissue long after exposure [12,35,50,51]. This means that
translocation to circulation may occur for months or even
years and extrapulmonary effects may increase or even arise
long after exposure has ended.
Ryman Rasmussen et al. showed that inhaled MWCNT
(L:0.5–40 lm, D:10–50 nm, 1 or 30 mg/m3 for 6 hr) translo-
cated to the subpleural region of the lung. CNT translocated
rapidly (1 day) and were observed in the subpleura until the
end of the experiment 14 weeks after exposure. CNT were
observed both within macrophages, within subpleural mes-
enchymal cells and within the collagen matrix of the sub-
pleura. The observations suggest migration of CNT as
engulfed cargo within macrophages [52].
In line with this, Mercer et al. show that 0.6% of the pul-
monary deposited dose after pharyngeal aspiration had translo-
cated to the subpleura by day 1. The authors documented that
MWCNT (Mitsui, XNRI MWNT-7, L:3.9 lm, D: 49 nm)
penetrations of alveolar macrophages, the alveolar wall and
visceral pleura were very frequent and sustained. They esti-
mated that a pulmonary dose of 40 lg caused in excess of
20 million cellular penetrations throughout the lung and that
56 days post-exposure one of 400 fibre penetrations will be in
the subpleural or intrapleural space [53].
Another study by the same group identified MWCNT (Mit-
sui, as above) inside as well as protruding from alveolar
macrophages. Many of the penetrations went completely
through both the cell and the cell nucleus. One hour after pha-
ryngeal aspiration, MWCNT were engulfed by macrophages
and by type 1 alveolar epithelial cells. At later time-points,
MWCNT were not observed on the surface of epithelial cells,
but were located within the alveolar interstitium, interstitial
cells or alveolar macrophages. MWCNT were detected within
the pleura 56 days post-pharyngeal aspiration [54]. Cellular
penetrations have also been confirmed in mice studies of
intratracheal instillation of short, tangled and long, thick CNT.
Using several EM techniques, both tubes were observed both
freely and inside vesicles in the cell cytosol. CNT were, how-
ever, never observed inside the nucleus [20,55].
A recent review by Donaldson et al. argued that this
migration into the intrapleural space is common for a smal-
ler fraction of all particles deposited in the distal lung. A
suggested mechanism of particle clearance from the pleura is
that particles follow lymph fluid through narrow holes
(stomata) in the parietal pleura. However, the long fibres
cannot migrate through the small stomata, leading to reten-
tion, local inflammation and pleural pathology, for example
mesothelioma [5].
It should be underlined that the above publications only
focused on intrapulmonary translocation and made no attempts
to assess a further translocation to extrapulmonary organs.
However, others have detected such a translocation. Ingle
et al. detected a direct Raman signal of the inhaled unmodi-
fied SWCNT in the blood of mice [22], thereby showing the
possibility of secondary organ exposure. They did not detect
whether the CNT were excreted or accumulated.
Lin et al. detected the vast majority of instilled 125I-
SWCNT in trachea and the GI tract, suggesting mucociliary
clearance. However, small amounts (0.02–0.12% of the dose/g
tissue) were detected in 16 other tissues.
In another study, translocation of 10 lg taurine-functiona-
lized-MWCNT labelled with 14C (L: 10–600 nm, D: 10–
15 nm) was followed after instillation in mice [38]. The
instilled 14C-tau-MWCNT was only detected in the lungs,
declining from 78% of the administered dose at day 1–20% at
day 28. No 14C activity was detected in blood or key organs
such as liver, spleen, kidneys, at any of the post-exposure
time-points. However, the specific activity of the administered
14C-tau-MWCNT was 2700 cpm/lg; thus, the level of
radioactive labelling might be too low to detect translocation
in the order of a few per mille, which would be an expected
level.
After instillation of 200 or 550 lg unmodified MWCNT,
about 30% was cleared within 24 hr. The remaining 70%
(120–150 lg and 280–380 lg, respectively) remained in the
lung throughout 1 year with no indications of reduction.
Tubes were not detected in liver or brain, but were detected in
peribronchial lymph nodes [50]. Elgrabli et al., [35] also
Table 1.
Detecting CNT in biological tissues with various methods.
Methods Specificity Sensitivity Quantitative Comment
Microscopy High–Medium Low No-semi Difficult to detect. Misinterpretation
Raman High Medium Semi (Yes) Poor signal-to-noise ratio
NIR fluorescence High Medium Semi (Yes) Signal decreases strongly with depth
Radioactivity
Skeleton-enriched High High–Medium Yes Radioactivity cannot detach from the tube
Small constructs High–Medium High–Medium Yes The strength of the covalent bond to the CNT
Large constructs High–Medium High–Medium Yes The strength of the entire construct
Metal tracers High–Medium Medium–Low Yes The attachment and mass of the tracers
Specificity is the ability of a method to correctly identify CNT from a signal. Sensitivity describes the chance of detecting small concentrations.
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detected a translocation of Ni associated with the pristine
MWCNT to the lymph nodes of rats (1, 10, 100 lg; L: 0.5–2
D: 20–50 nm). But in contrast to Shinohara, they found the
lung burden continuously decreasing; 63–78% of the instilled
Ni was detected in the lung at days 1, 7 and 30. After
3 months, 38% of the Ni was detected in the lung, and after
6 months, 16% was still detected in the lung [35].
Mercer et al. exposed mice for MWCNT aerosol (5 mg/m3,
5 hr/days, 4 days/week for 3 weeks) and observed that all
analysed tissue contained MWCNT, albeit in small amounts.
The major extrapulmonary site was the tracheobronchial
lymph nodes, which were found to contain 1 and 7% of the
lung burden (28 lg) at 1 day and 336 days post-exposure,
respectively. All other analysed tissues, liver, kidney, heart,
brain, chest wall and diaphragm, contained ≤0.004% or
≤0.027% of the pulmonary dose at day 1 and day 336, respec-
tively. The CNT were detected directly via light microscopy
and hyperspectral imaging [21].
Czarny et al. [31] used pharyngeal aspiration to deposit
20 lg 14C skeleton-labelled MWCNT (L: 3.9 lm, D: 40 nm).
Radioimaging showed that the pulmonary radioactivity
decreased from 100% to 10% over 3 months. In the same
time, small amounts of MWCNT translocated to distant organs
with a clear increase over time. An increase in liver, spleen,
kidney and bone marrow was observed from day 7 to day
360. Liver and spleen contained about 0.8% and 0.2% of the
exposed dose, respectively, 1 year after exposure. Kidney and
bone marrow contained much less <0.2% of the pulmonary
dose. A possible secondary uptake from the GI tract was elim-
inated, as no translocation to spleen and liver was observed
after an oral exposure (50 lg). The authors concluded that the
observed translocation after lung exposure occurred through
the pulmonary epithelium only [31].
Biodistribution may be affected by specific biological dura-
bility and degradation. In one study, SWCNT (not specified)
were chemically cut [56] by sonication in H2SO4 and H2O2 to
create short SWCNT that were carboxylated at both ends.
These SWCNT could be degraded in vitro by a combination
of human myeloperoxidase and H2O2. While aspiration of
40 lg/mice of the chemically cut SWCNT induced inflamma-
tion 24 hr after pharyngeal aspiration, degraded SWCNT did
not cause inflammation. This indicates that the extent to which
the CNT are biodegradable is a major determinant of the
inflammatory response.
In summary, the above studies show that the majority of the
deposited dose remains in the lung or is cleared towards the
GI tract. However, a significant fraction appears to translocate
to the near pulmonary region including subpleura/pleura (be-
low 1%), lymph nodes (up to 7%) and to distal organs includ-
ing liver and spleen of approximately 1% of the deposited
dose. For the translocation to distant organs, we add great
value to Czarny et al. [31]. The study design was valuable
with strongly radioactive skeleton 14C-enriched MWCNT,
allowing for the detection of ≥22 intact CNT in tissue samples
[31]. Translocation was much higher than previously estimated
(~0.03% of the pulmonary dose was estimated to be in the
liver at day 336) [21]. The dose was estimated from results of
semiquantitative hyperspectral microscopy. The spleen was
not examined. It should be noted that Czarny et al. conducted
a pharyngeal aspiration study, whereas Mercer’s group con-
ducted an inhalation study. However, it should also be noted
that about 20% of the aspirated dose was still present in the
lung 1 year post-exposure, and accumulation in lung and
spleen could thus continue for even longer [31].
Oral.
It is well known that one mechanism of clearing particles
from the pulmonary region is via the mucociliary escalator
into the gastrointestinal tract for excretion via faeces. How-
ever, such transport upwards to the pharynx will lead to the
particles being swallowed for a pass through the GI tract and
a second possibility for systemic translocation through the
intestine. This translocation occurs after all pulmonary expo-
sures with a post-exposure time longer than a few hours.
Only few studies have attempted to determine biodistribu-
tion via the oral route. Heifang Wang et al. showed that small
hydroxylated SWCNT (125I-labelled KOH-SWCNT, L:
300 nm, D: 1.4 nm) could easily distribute to organs and
compartments and basically moved freely and rapidly around
the body despite a large molecular weight of 600 kDa. Three
hours after oral administration of 1.5 lg, the SWCNT (125I
activity) were detected in all 12 analysed organs with highest
concentrations in stomach, kidney, lungs and bone and with
lowest concentrations in brain, heart and muscle [57].
Agglomerates of SWCNT (160 nm) with embedded
gadolinium (Gd) nanoparticles did not show any signs of
uptake after oral administration (2 mg/mouse). Gd was
detected throughout the GI tract, but was not detected in
blood, liver or spleen. About 80% was excreted within 8 hr
and almost 100% within 24 hr [37].
Deng et al. studied distribution after 10 lg orally dosed
small MWCNT (14C-tau-labelled, L: 10–600 nm, D: 10–
15 nm). These were detected in stomach, small intestine and
large intestine, ending up in faeces. Radioactivity passed
downstream over time. About 74% of the administered dose
was excreted in faeces within 12 hr post-exposure. No label-
ling was detected in blood, indicating that 14C-tau-MWCNT
was neither absorbed from the gastrointestinal tract nor entered
the blood circulation in detectable concentrations [38].
Czarny et al. [31] detected translocation to various organs
after lung deposition of 14C-enriched MWCNT. To determine
the route of translocation, they performed an oral exposure
study (50 lg; L: 3.9 lm, D: 40 nm). Twenty-four hours post-
exposure, 95  15% of the dose was found in the GI tract
and faeces, and no radioactivity was detected in the GI tract
and faeces from 4 days post-exposure. No radioactivity was
detected in spleen and liver [31].
There are huge differences in biodistribution between these
studies of ingested CNT, from no biodistribution to complete
availability in all tested organs. Besides the differences in tra-
cer and detection techniques used, the blatant disparity may be
due to the size and shape of the tubes presented to the GI
tract. The tubes had somewhat similar length, but not only
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were the MWCNT used by Deng et al. about 10 times thicker,
they also had a more flexible appearance than the straight nee-
dle-shaped SWCNT used in Heifang Wang’s study (fig. 3).
The tubes used by Nakamura were about 3 nm in diameter
and 70 nm in length, but were 160-nm agglomerates in the
exposure suspension (distilled water). Translocated tubes
would only be detected if Gd also translocated.
Even though size may be important, it should be mentioned
that SWCNT were detected indirectly via 125I. In order to
strengthen that the free distribution of SWCNT was not
caused by 125I alone, the authors showed that no unbound
125I ions were adsorbed to the surface of the SWCNT. Addi-
tionally, a somewhat different distribution profile was
observed for Na 125I compared to 125I-SWCNT. This led the
authors to conclude that the observed biodistribution was of
125I-SWCNT and not 125I.
Overall, with one exception, there appears to be no obvious
tissue uptake from the GI tract of CNT. The same has
been observed previously with other nanomaterials such as
125I–graphene [58] and several TiO2 materials [59].
Biological distribution from blood (IV exposure).
Nanomedicine may completely transform and revolutionize
health care, and CNT make their mark within this field.
Thus, it is not surprising that there are several publications
on biodistribution of CNT after IV injection. However, it is
of paramount importance that the pharmacokinetics and bio-
logical effects of promising candidates are fully understood
before ideas are propelled to the development of medical
agents. These studies mainly serve as examples of biodistri-
bution of CNT translocating from the lung to systemic circu-
lation. However, in the case of larger agglomerates being
present in the exposure, it should be noted that after IV
injection, the first capillary network encountered will be the
pulmonary system.
Unmodified CNT. 13C-enriched SWCNT (L: 2–3 lm, D: 10–
30 nm (bundles)) were injected in the tail vein and
biodistribution was studied up to 28 days [30]. The authors
excluded elimination via urine, but mentioned that very little
excretion could be determined in faeces. Therefore, the pristine
SWCNT were suggested to mainly be distributed and remain
internally. 13C was detected in a variety of organs, with highest
concentrations in the liver (21, 18 and 21% of the dose,
respectively, after 1, 7 and 28 days), lung (15, 13 and 9% of
the dose, respectively) and spleen (1, 2 and 2% of the dose). In
the liver, SWCNT were localized in Kupffer cells as shown by
electron microscopy. SWCNT were also detected in the lungs
by TEM [30]. Unique for this study was the employment of a
direct measure of crystal structure of 13C-enriched CNT. These
results are thus not biased by biodistribution of tracers that
were detached from the CNT. The detected isotope ratios
(13C/12C) were related directly to the concentrations of
13C-SWNT in the various analysed organs; however, the
method has a relatively low detection sensitivity (1 ppm) as the
presence of natural 13C is relatively high (1.1% of C).
These results were supported by another study from the
same group [25]. Identical SWCNT (L: 2–3 lm, D: 10–30 nm
(bundles)) were injected IV in mice. SWCNT were detected
by Raman spectroscopy in lung, liver and spleen 90 days
post-injection. The intensity was strongest in the lung, and
although the analysis was qualitative, the authors noted that
the accumulated amounts in the lungs were remarkable.
SWCNT were also visible in light microscopy as black spots
and by TEM in lysates of liver and lung from the high dose
(1 mg/mouse) after 90 days [25].
Unmodified non-commercially available SWCNT (L:
300 nm, D: 1 nm) were injected IV into rabbits (75 lg/ani-
mal, 20 lg/kg) and the SWCNT were detected using near-
infrared fluorescence [28]. Injected SWCNT were quickly cov-
ered with blood proteins, and the blood concentration had a
Fig. 3. TEM images of CNT used in oral biodistribution experiments. Left: MWCNT (L: 10–600 nm, D: 10–15 nm). Right: SWCNT (L: 300 nm,
D: 1.4 nm (bundles)). Reprinted with permission from J Nanosci. Nanotech. [57] and Carbon [38].
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half-life of 1 hr. The experiment was terminated after 24 hr,
and SWCNT were clearly detected in the liver as the only of
many organs [28].
Classic physiology suggests that once particles are in the
blood circulation, there are two common excretion pathways.
These are known as renal and the hepatobiliary clearance.
Small particles are often excreted in the urine. However, this
requires passage through the renal corpuscle with the vast num-
ber of perforations (fenestrations/glomerular basement mem-
brane/filtration slits/epithelial podocytes) of the endothelium
being <10 nm and with a small subset (<2%) being 15–20 nm
[60]. This means that there appears to be a size cut-off point
and that larger particles tend to accumulate within the body,
primarily within Kupffer cells of the liver. The above-men-
tioned results support these thoughts. Given the size of these
physically large entities made up of agglomerated unmodified
particles, they are not excreted but primarily stored in liver tis-
sue as expected. However, the cause for CNT to move from the
bloodstream to lung tissue as observed in one of the publica-
tions is unknown. However, one hypothesis could be that when
injected into circulation via a tail vein, the lung will be the first
organ encountered. If CNT agglomerates beyond the diameter
of the fine capillaries of the lungs (>2 lm) were injected, these
could be trapped and retained in the lung capillaries.
Modified CNT. Carbon nanotubes have been proposed as
possible carriers for drugs, proteins, peptides and nucleic acids
(for gene transfer or gene silencing) and as stable
biomolecules in diagnostic applications. For such applications,
chemical modifications of the CNT surface may be necessary
to target specific organs. Several groups have actively
explored this area, and several papers have been published.
SWCNT. One study investigated 64Cu-radiolabelled-DOTA-
PEG-SWCNT (L: 100–300 nm, D: 1–5 nm). It was found that
small and large PEG chains-SWCNT had blood circulation
half-lives of 0.5 and 2 hr, respectively. There was a prominent
uptake in the liver and to a much lesser extent spleen and
kidney. Larger PEG chain caused a slower blood clearance
and lower concentration in liver [48].
A second study using water-soluble and 111In-labelled
SWCNT (L: 0.1–1 lm, D: 1.4 nm) for in vivo biodistribution
found a fast blood clearance with only 3% and 0.4% of the
dose/gram blood after 1 and 20 hr, respectively. Tissue analy-
sis indicated that the major sites of 111In accumulation were
the kidney followed by liver, spleen and, to a much lesser
extent, bone. 111In cleared the kidneys more rapidly than the
spleen and liver. Urine was collected 1 hr post-injection and
some radioactivity was noted, indicating a possible urine
excretion of the tracer [47]. Only their experiments with non-
tumour-targeting constructs were considered here.
Carlos Villa and colleagues used SWCNT-111In-(DOTA)-
coupled to modified DNA oligonucleotides (L: 0.05–0.1 lm,
D: ~1–1.5 nm). The results suggested a relatively fast clear-
ance from the blood with 0.4% of the dose/gram blood
remaining at 24 hr. SWCNT were mainly located in liver, kid-
ney and spleen. Lower concentration was detected in seven
additional organs. The organ radioactivity was relatively simi-
lar throughout the experiment (1–96 hr) [41].
Hydroxylated and 131I-labelled SWCNT (L: 0.3 lm, D:
1.4 nm) were used in a short-term (2-min. to 1-hr) biodistribu-
tion study. Radioactivity was found all over the body (except
brain) within 2 min. Kidneys, liver, bone, spleen, stomach and
lungs were the major target organs in mentioned order.
SWCNT in heart, lungs, skin and muscle tissues were corre-
lated with the content in the blood, illustrating both that the
bloodstream brings the modified SWCNT to the whole body
and that the SWCNT did not accumulate in these tissues.
Blood half-life was about 4 min. immediately after the injec-
tion and about 50 min. at the end of the experiment (1 hr
post-injection) [61].
Kang et al. showed blood clearance with a half-life of 3–
4 hr, with a concomitant rapid uptake of high levels (~50% of
the dose/g) in liver of mice using 488F-chitosan-functionalized
SWCNT (before functionalization L: 0.05–0.2 lm, D: 1–
3 nm). The amount of accumulated SWCNT in liver did not
decrease during the 24-hr period and led to pathological
changes such as injury of macrophages, cellular swelling and
inflammation and blood coagulation. A similar uptake was
observed in spleen and kidney; however, the authors did not
observe obvious pathological changes in these organs [27].
Using Raman spectroscopy of SWCNT (L:~100 nm, D: 1–
2 nm) non-covalently functionalized by three different lengths
of PEG chains (2, 5 and 7 kDa), it was again shown that liver
(30–65% of the dose/g tissue) and spleen (19–30% of the
dose/gram tissue) are the major sites of accumulation (24 hr)
followed by bone, kidney, intestine, stomach and lung. The
authors suggested that the majority of CNT accumulate in the
liver and renal excretion only occurs for the shortest of the
SWCNT. The content of SWCNT in six other tested organs
was below the detection limit. Blood circulation time, defined
as the time until the blood SWCNT level had dropped to 5%
of the dose/gram, was between 1 and 15 hr. The decay rate
depended on the modification and size of PEG chains in such
a way that functionalization with larger PEG chains increased
the circulation time. Additionally, the authors reported a
reduced uptake in liver and spleen for largest PEG chain-mod-
ified SWCNT compared with the small 2-kDa modified [24].
The results were in line with a previous publication by the
same group [48] in which a large-sized PEG chain 5.4 kDa
caused a relatively slower blood clearance and concentration
in liver than a smaller one of 2 kDa.
PEG1500N-functionalized, acid-treated and thermally
annealed SWCNT (L: 0.3–1 lm; D not reported) were admin-
istered to mice in order to clarify distribution and biological
defunctionalization using Raman and photoluminescence mea-
surements. Only two organs were analysed (liver and spleen)
and SWCNT were detected at 1, 4 and 8 weeks post-exposure.
Additionally, results suggest that a defunctionalization of the
amide linkages between the PEG occurred in the liver (4 and
8 weeks), but not in the spleen [26].
All eight above-mentioned studies included SWCNT with
small dimensions (L: <1 lm, D: <2 nm). In seven of them,
blood clearance was measured and determined to be relatively
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fast. However, the unit was not identical as some use half-life
and others the remaining actual dose or a fraction of the
injected dose remaining, and yet others a fraction of the dose/
g blood at a certain time-point. The half-life varied from a
few minutes to several hours depending on the material. The
shortest blood half-life (4 min.) was observed with hydroxy-
lated and 131I-labelled SWCNT (L: 0.3 lm, D: 1.4 nm). This
was much shorter than the half-life (4 hr) of an otherwise sim-
ilar SWCNT (size before functionalization L: 0.05–0.2 lm, D:
1–3 nm) functionalized by adding 3- to 5-kDa biocompatible
polymers (chitosan) and green fluorescent dye. The same trend
was observed in [24,48] where a larger size of PEG chain was
related to increased circulation time and decreased clearance
(5% of the dose/gram was between 1 and 15 hr). In two of
the papers, kidney followed by liver was mentioned as the pri-
mary site of accumulation. In the remaining six papers, liver
was the major target organ with much less in spleen and kid-
ney. This distribution was also observed in a study by Schip-
per et al. despite the use of extremely long SWCNT. Mice
were injected with oxidized or non-oxidized, non-covalently
PEGylated SWCNT (L: 100–300 lm, D: 1–5 nm, oxidized
CNT: L: 0.05–0.2 lm). Distribution was determined by histol-
ogy and Raman spectroscopy. Nanotubes persisted within liver
and spleen macrophages until the termination of the experi-
ment 4 months post-exposure without apparent toxicity. There
were no changes in survival and clinical parameters of toxicity
over the 4 months [23].
Wang et al. used hydroxylated SWCNT labelled with 125I
(L: 300 nm, D: 1.4 nm). The distribution pattern of the IV-
injected SWCNT mimicked that after the oral exposure
described above. The nanotubes moved easily to all compart-
ments and tissues of the body. Highest amounts were detected
in stomach, kidney, lungs and bone, and very small amounts
were detected in brain. An analysis of the excretion over
11 days demonstrated that about 80% of the total injected
radiolabel was collected in faeces and urine (94% in urine and
6% in faeces) [57].
Water-soluble, SWCNT (L: 0.3–1 lm, D: 1 nm) functional-
ized with DTPA and labelled with indium (111In) were used
for distribution and imaging analyses [40]. Results indicated
that the SWCNT were not retained in organs such as liver and
spleen, but were cleared from blood circulation with a half-life
of about 3.5 hr through the renal excretion route. At 30 min.,
largest amounts of 111In were detected in muscle tissue (49–
63% of dose) and skin (8–36% of the dose), whereas at 3 and
24 hr, very low levels were observed in all tested organs.
No labelling was observed in the livers. Additionally, DTPA-
SWCNT were identified in urine by transmission electron
microscopy. In these analyses, it was found that SWCNT
primarily existed as bundles of 10–40 tubes (D: 13–40 nm). It
is possible that the SWCNT were singular when passing the
kidneys and then agglomerated in the urine or during the
sample preparation.
SWCNT modified with lysine and DOTA [111In](SWCNT-
Lys-DOTA[111In]) were shown to be excreted in urine after
injection in mice. Thirty-four percentage was in the urine after
30 min. Only a smaller percentage remained in the mice after
90 min. (kidneys 1.1% of the dose/g tissue; liver 0.2–0.3% of
the dose/g tissue) [44].
Regardless of length, short (100 nm), intermediate (300–
1000 nm) or long (100–300 lm), all except three publications
[40,44,57] found liver to be the primary site of accumulation.
The most common secondary targets were kidney and spleen.
It thus points to a distribution profile similar to most small NP
[62]. For unmodified SWCNT, lung is also mentioned which
may be due to the presence of larger agglomerates (>2 lm).
However, it should be noted that the authors did mention
agglomerates in the suspension (D: 10–30 nm and L:
2–3 lm), but these appeared to be too small to explain the
pulmonary deposition, unless adsorption directly to the
endothelium via hydrophobic interactions or needle-like
piercing of the membranes is involved [25,30].
According to renal physiology, only very small particles
can be excreted in the urine. SWCNT may be much larger
than other molecules previously shown unable to pass the kid-
neys to urine (<30–50 kDa). However, they do have a unique
structure that enables just this and thus calls for modifications
to the traditional rules for renal filtration. The diameter (thick-
ness) of well-dispersed SWCNT is far below the filtrating size
of the renal corpuscle perforations (<10 nm) [60].
McDevitt et al. [46] proposed the hypothesis that long, thin
SWCNT fibres could negotiate the glomerular filtration on the
longitudinal axis (like spaghetti through a sieve). This idea
has been further elaborated by Ruggiero in [49]. The authors
injected a modified SWCNT (SWCNT-86Y-DOTA-AF488-
AF680; D 1 nm, 100 ≤ L ≤ 500 nm, MW: 150–750 kDa)
and found that despite these features,  65% remained within
the kidneys 20 min. post-injection. No toxicity or modifica-
tions of kidney structure were observed. In addition, the
authors provided a theoretical model that suggested that the
velocity of the flow at the glomerular perforations (fenestra)
(2 9 105 m/sec.) is sufficiently high to steer the CNT into
the pores in the longitudinal axis. This provides a physical
explanation for the observed urine clearance. It should be
noted that larger surface modifications may well render the
construct less able or even unsuitable for renal clearance. For
example, addition of large PEG chains especially with
branched structures to the surface of SWCNT altered the PK
profiles away from kidney filtration [24].
Table 2 compiles main results from studies using SWCNT
labelled with radiotracer attached to DTPA or DOTA. One
study showed no difference in distribution profile when
DTPA-111In is replaced with DOTA-111In [43]. Despite the
great similarity in exposure conditions, the results vary to a
great extent, both in blood clearance and in organ accumula-
tion – from almost all in kidneys and nothing in liver/spleen
[40] to the vice versa with most in liver and spleen with less
[47] or nothing [48] in kidneys. It should be noted that the lat-
ter study used PEGylated SWCNT, which may have caused
the reduced kidney filtration. However, still large differences
are observed within this group but also when compared to the
publications examining distribution of SWCNT with a direct
SWCNT detection (Raman, NIR fluorescence and skeleton-
enriched SWCNT) all mentioning liver, spleen and lung as
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target organs and with no or very limited urinary excretion.
One hypothesis might be that three studies used non-cova-
lently PEGylated SWCNT [23,24,26], one used SWCNT non-
covalent functionalized with chitosan [27], whereas [28] and
[25] used pristine SWCNT, which may have partially agglom-
erated. Combined, these modifications may have aided in
evading kidney filtration. Also, it should be noted that several
groups have shown that SWCNT can pass kidney filtration.
MWCNT. The distribution of 14C-tau-MWCNT (10 lg, L:
10–600 nm, D: 10–15 nm) has also been investigated after
intravenous injection. Within 10 min., about 80% of the
exposed dose had accumulated in the liver. The detected
values in liver varied between 75 and 85% through the first
month. After 90 days, 20% of the dose was still localized to
the liver. TEM images clearly showed MWCNT localized in
the Kupffer cells. Smaller amounts (1–5%) were detected in
spleen and lung. The results indicated elimination from lung
tissue, but a constant or slight build-up in spleen for the
90 days [38].
Taurine-covalently functionalized and Tween-80-wrapped
nanotubes labelled with 125I (125I-tau-MWCNT and
125I-Tween-MWCNT, 10 lg) were dosed IV into mice [33].
After 5 min., about 80% of 125I-tau-MWCNT was in the liver
and smaller amounts in spleen and temporarily in the lung.
Liver concentration remained high and ended at 75% of the
dose after 6 hr. 125I-Tween-MWCNT was found to be dis-
tributed to the liver, spleen and lung, but also into stomach,
kidney, large and small intestine. There were indications that
Tween-MWCNT partly evaded liver capture, possible due to
dispersion properties of Tween. It should be noted that these
results are very similar to those mentioned above by the same
group using 14C-tau-MWCNT [33].
14C-MWCNT (L: 3–4 lm, D: ca. 100 nm) was sonicated in
pure rat serum until the formation of a stable suspension. After
IV delivery in rats, the MWCNT were cleared from the blood
(NB: 24 hr was the shortest time-point) and distributed into
mainly liver. Lower amounts were detected in lungs, spleen
and kidneys, whereas no radioactivity was detected in brain,
heart, bones, stomach and muscle (i.e. less than 10 pg in each
organ). Optical microscopy revealed dark clusters in lung and
liver that coincided with radioactive hot spots. Decreasing
radioactivity was observed in all organs over the course of the
experiment [32]. This MWCNT experiment should be noted
as the C-C covalent bond between CNT and the external 14C
is very strong and much more stable than other radionu-
cleotide complexes used in other studies.
Thick (D: 39.5 nm) and thin (D: 9.2 nm) MWCNT of simi-
lar length were surface-modified with amines, whole IgG anti-
body or the antigen binding region of IgG modified. All
contained the radiotracer [111In]DTPA. Interestingly, the modi-
fications appeared not to influence the distribution, whereas
diameter did. The thick MWCNT were primarily located in
spleen and liver with much less in lungs and miniscule
amounts in another eight tested organs including kidneys. The
narrow MWCNT were primarily located in lungs with less in
spleen and liver and far less in heart and kidney and with very
low amounts in the remaining organs. The authors suggested
that the alveolar macrophages play a role in the increased
transport of narrow CNT to lung tissue [45].
Multi-walled carbon nanotubes were aminated and modified
with DTPA[111In] before being injected into mice. The mate-
rial accumulated instantly (5 min.) in the lungs (27% of the
dose) and liver (19.8% of the dose). Similar concentration was
detected throughout the 24-hr period. Low levels (~1–7% of
the dose) were detected in skin, spleen, kidneys, muscle and
bone. Brain, stomach and heart all had well below 1% of the
dose. The blood contained 14% of the dose at 5 min., which
decreased at all measuring times to reach 1% of the dose after
24 hr. Body was perfused to avoid [111In] signal interference
from blood [63].
Al-Jamal et al. showed that 111In-DTPA attached via pyrro-
lidine amide bonds (111In-DTPA-MWCNT) led to about 58–
68% distribution to the liver and 2.6–4% in the spleen of the
dose. Only very small amounts ended up in the lung and kid-
neys. Approximately tripling the number of functionalization
reduced liver accumulation (42% of the dose) with a concomi-
tant small increase in spleen (5%) and lung (2%). A somewhat
increased signal was observed in the bladder for the most
functionalized MWCNT compared to the MWCNT with lower
levels of functionalization [43].
Multi-walled carbon nanotubes (outer/inner D: 35/10 nm. L:
0.2 lm and up) were oxidized, aminated and loaded with Pt
drugs inside the MWCNT. After IV injection, Pt was mainly
detected in the livers. When viewed as dose/g tissue, similar
levels were detected in liver, kidney, spleen and lung. Some
Table 2.
Studies using SWCNT with radiotracer-labelled DTPA or DOTA.
SWCNT Clearance (blood) Major sites of deposition References
DTPA-111In T1/2: 3–3.5 hr Kidneys. Much less in skin, liver [40]
DOTA-111In 1 hr: 2.8%ID/g blood
20 hr: 0.4%ID/g blood
Kidneys. Much less in liver, spleen, bone [47]
DOTA-111In 24 hr: 0.4%ID/g blood Liver, kidneys. Much less in spleen [41]
PEG-DOTA-64Cu T1/2: 0.5–2 hr depending on PEG size Liver. Much less in spleen [48]
DOTA-86Y 86Y cleared at 3 hr Liver, spleen. Less in kidneys, bone [46]
DOTA-86Y T1/2: 6 min. Kidneys. Less in liver, spleen [49]
DOTA-111In 34% & 91% in urine after 30 min. and 12 hr Kidneys. Less in liver [44]
Bold text indicates a clear major site of deposition. DOTA, 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid; DTPA, diethylen-triamine-
penta-acetic dianhydride.
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urine excretion of Pt. MWCNT was verified in liver tissue via
microscopy [36].
Water-soluble MWCNT (L: 0.5–2 lm, D: 20–30 nm) func-
tionalized with DTPA and labelled with indium (111In) were
used for urine excretion studies. DTPA-MWCNT were identi-
fied by transmission electron microscopy in the urine. In this
analysis, the MWCNT were primarily detected as individual
fibres/tubes (D: 30–38 nm) [40]. In another study by the same
group, 111In-labelled DTPA-MWCNT were tracked in rats
(size before functionalization: L: 0.5–2 lm, D: 20–30 nm)
[42]. Imaging showed that within a minute, the CNT began to
accumulate in the kidneys and bladder. At 30 min., most of
the detected activity was in the kidneys/bladder. At 6 hr,
almost all CNT eliminated via renal excretion route. At 24 hr,
only residual levels were detected in liver, spleen, kidneys and
bladder. Urinary excretion of the vast majority of radiola-
belling (nanotubes) was confirmed at 24 hr, where it was
shown that 11.5% of the dose/g tissue was in the urine,
whereas the liver, spleen, bladder and kidneys all had content
below 1%. Kidney histology (24 hr) showed normal renal
morphology without MWCNT accumulation. The rapid uri-
nary clearance of MWCNT observed by Lacerda et al. is in
contrast to the papers mentioned above. The authors all
reported a rapid blood clearance profile predominantly leading
to hepatic accumulation. The urinary clearance of MWCNT is
also in contrast to the traditional rules for renal filtration
(<30–50 kDa), with only a small subset of pores (2%) allow-
ing passage of material up to 20 nm, and to the above-men-
tioned exception of longitudinal filtration of thin SWCNT,
even if the MWCNT were mentioned as being predominantly
individualized with average dimensions of 20–30 nm (before
functionalization). Smaller dimensions for a subset of the CNT
appear not to be a possible explanation as the MWCNT were
predominately located in this excretion pathway.
It should be mentioned that Wei et al. found 7% of the
exposed dose of oxidized and technetium-labelled MWCNT
(99mTc-oMWNT, L: 1–10 lm D: 10–30 nm) in collected urine
in the first 2 hr after IV exposure. Another 2.6% was detected
in the urine between 2 and 25 hr [64]. One other group
observed a larger urinary excretion. Guo et al. used glu-
cosamine and technetium-modified MWCNT (99mTc-MWNT-
G; L: >10 lm, D: 20–40 nm) for intraperitoneal deposition in
mice. Activity was mainly located in the urine/faeces of the
mice after 24 hr. In the Lacerda and Singh papers, a construct
of 111In-DTPA-MWNT (size before functionalization: L: 0.5–
2 lm, D: 20–30) was used [40,42]. However, using the same
construct, 111In-DTPA-MWNT, the same group was not able
to reproduce these results in mice as only minor levels were
located in the urine and/or kidneys. These include tubes with
identical dimensions [63], same diameter, but similar and
shorter lengths [43] and tubes with thicker and thinner diame-
ter with similar length [45]. Therefore, the findings on urinary
clearance should be reproduced and confirmed. However, it
should be emphasized that as several papers/groups now con-
firm at least small amounts in kidney/urine, the phenomenon
should not be ruled out completely, but elaborated and exam-
ined further. If excluding those with predominately urine
excretion, it appears again that for both SW and MWCNT,
liver appeared to be the major target followed by spleen, lung
and kidney.
There is no doubt that the different modifications will
affect the distribution of IV-injected CNT. Larger side chains
may postpone or render urine excretion impossible. Modifica-
tions may also improve the CNT dispersibility in physiologi-
cal and biological compatible media, causing a shift in size
towards a suspension of many small agglomerates and indi-
vidual particles, possibly increasing excretion. It is, however,
a major challenge to compare different chemical preparations,
functionalizations and study designs. Although the overall
distribution changes were not great, it was shown that
increasing the level of surface modifications reduced the
deposition in the liver from 58 to 68% down to 42% of the
dose [43].
Biological distribution after peritoneal deposition.
Intraperitoneal injection (IP) is an injection into the body cav-
ity below the diaphragm. IP is rarely used in human beings,
but is frequently used in veterinary medicine and in scientific
experiments. Only a few papers have described the biological
distribution of nanotubes after a peritoneal deposition.
Wang et al. have used hydroxylated SWCNT labelled with
125I [57] and 131I [61]. The distribution pattern of the IP-
injected nanotubes at 3 hr was similar to that observed after
oral and IV exposure described above. Highest amounts were
detected in stomach, kidney, lungs and bone, and very small
amounts were detected in brain. At 6 hr, amounts were highest
in stomach, kidney and bone. At 3 and 6 days, nanotubes
were only detected in kidney and bone. Very low radiola-
belling was detected in all other organs. A large urine excre-
tion was observed within the first 2 days. Eighty percentage
was excreted during the first 11 days (94% in urine and 6% in
faeces) [57]. In the second study, the hydroxylated 131I-
labelled SWCNT were used in a short-term (2-min. to 1-hr)
biodistribution. Radioactivity was found all over the body (ex-
cept brain) within 2 min. Bone, kidney, stomach, blood,
spleen and liver are in mentioned order the major target
organs. Lower concentrations were detected in all other
organs. Blood half-life was about 4 and 55 min. in the begin-
ning and at end of the experiment, respectively [61].
Another study with functionalized SWCNT (D: 1.4 nm. L:
0.1–1 lm) performed in athymic mice showed a distribution
in liver, kidney, spleen and bone with 7.5, 8.5, 9.7 and 1.4%
of the dose/g, respectively, after 3 hr and 8.8, 5.4, 7.5 and
1.6% of the dose/g, respectively, after 24 hr. The radioactivity
persisted longer in the IP cavity, which seemed to reduce
accumulation in liver and spleen. The CNT did not move
around the body as similar-sized proteins would [46].
Results by Tsyboulski et al. are in contrast to those above.
Unmodified SWCNT predominantly accumulated in liver
(43 lg/g tissue), spleen (47 lg/g tissue) and kidneys (2.4 lg/g
tissue). About 65 lg (38% of the dose) of SWCNT was pre-
sent in these organs 3 days after SWCNT injection. There was
no attempt to measure excretion (urine/faeces) [65].
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When using water-soluble MWCNT (L: 10 sec. of lm, D:
20–40 nm) functionalized with glucosamine and labelled with
radioactive technetium (99mTc-MWCNT-G), Guo et al.
showed that blood half-life was 5.5 hr and that CNT moved
easily throughout the compartments and tissues of the body.
The major organs were the stomach and the enterogastric area.
A subsequent excretion experiment (24 hr) showed that about
70% of the activity was collected in urine/faeces. Results indi-
cated that a vast majority of 99mTc was bound to MWCNT-G
in urine after 24 hr and that there was no free 99mTc [39].
Although only few studies on peritoneal exposure have been
performed, a distribution pattern starts to form. Unmodified
CNT remain in the cavity, but are also engulfed by the liver
and possibly spleen. With the exception of [86Y]-DOTA-
SWCNT [46], modified CNT (125I- or 131I-SWCNT-OH or
99mTc-MWCNT-G) appeared to move more freely around the
body. Two of the studies (SW and MWCNT) mention large
urine excretion. Excretion was not measured in the last, but a
large concentration of 131I was detected in the kidneys.
Conclusion
Here, we have reviewed the recent studies on in vivo biodistri-
bution of CNT. After more than a decade of research, it is
clear that a quantitative assessment of the distribution of CNT
remains a challenge and largely depends on the development
of new and improved detection techniques. Qualitative assess-
ments of CNT deposition in tissues are possible with the pre-
sent-day techniques, although these can be technically
demanding.
Importantly, it has been shown that after pulmonary deposi-
tion, CNT remain for months or even years in the lung. The
majority of CNT stay in the lung or are cleared via mucocil-
iary escalator towards the GI tract for a second opportunity
for uptake. However, there appears to be no uptake of CNT
from the GI tract, with the possible exception of functional-
ized very small SWCNT as shown by one study.
Several groups have reported that a significant fraction of
CNT translocate to the near pulmonary region including
lymph nodes (<7% of the pulmonary deposited dose), sub-
pleura and pleura (<1%) and to distal organs including liver,
spleen and bone marrow (~1%) after deposition of CNT in the
airways by inhalation, pharyngeal aspiration or intratracheal
instillation. These results clearly demonstrate the main sites of
CNT accumulation, which include pleura, a major site for
fibre-induced pulmonary diseases.
To locate other sites of accumulation, larger CNT exposures
can be dosed via, for example, IV injection. A large number
of studies have explored the biodistribution of pristine or func-
tionalized CNT after IV injection. Although this is a pharma-
cologically relevant exposure route, it should be considered
that the material enters circulation at different sites.
Unmodified CNT administered IV have a clear preference for
liver and lung. The hepatic uptake is similar to that observed for
the majority of NP and is in compliance with the traditional
blood clearance pathway of solid materials. As shown by
several groups, small particles (such as surface-modified
SWCNT) can be excreted in the urine. Larger particles or
agglomerates may be taken by Kupffer cells in the liver.
One possible mechanism for the CNT to deposit and concen-
trate in the lung is that when injected into circulation via a
tail vein, the lung will be the first organ capillary network
encountered. If some of the injected CNT agglomerates are
larger than the diameter of the fine capillaries of the lungs
(>2 lm), these may be trapped and retained in the lung.
Another possibility is that highly hydrophobic materials (such
as pristine CNT) may adhere strongly to the endothelium of
capillary network.
In general, IV injection studies have shown ample evidence
that CNT in blood circulation are cleared relatively fast with a
half-life of minutes or hours. Some functionalizations alter the
blood circulation time. The primary target organs for IV-
injected SWCNT are the liver with the most common sec-
ondary targets being kidney and spleen. For modified
SWCNT, kidney and urine excretion has been shown by sev-
eral groups. For MWCNT, the primary target is liver followed
by spleen, lung and kidney.
There is no doubt that functionalizations can either increase
or decrease the urinary excretion and that specific targeting
moiety can direct CNT to specific cell types. But the over-
whelming body of evidence shows that nanotubes without
such moieties will primarily be distributed to the liver where
they can stay for a long time. Several different kinds of CNT
have been observed in the liver up to 1 year after exposure.
In the present MiniReview, the biodistribution and biologi-
cal durability of CNT are discussed. The above-mentioned
results clearly show that CNT deposited in the lung translocate
to pleura and lymph nodes near the lung but also to distal
organs including liver and spleen – presumably via circulation.
Clearing rates appear to be very low. IV injections confirm
these primary targets, but additionally secondary targets
including lung and kidney are added. With the limited data
available, there appears not to be any uptake from the GI tract
of CNT. The consequence of translocation and CNT accumu-
lation in, for example, pleura, liver and spleen is presently
unknown, but is of great concern. Still, too little is known
about the influence of physical and chemical parameters on
the biodistribution and toxicity, and further research in this
area is of paramount importance.
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